{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:57:23Z","timestamp":1771333043751,"version":"3.50.1"},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2025,2]]},"abstract":"Abstract<\/jats:title>Background and Objectives<\/jats:title>Canadian Blood Services defers donors during and for 4\u2009months after oral pre\u2010exposure or post\u2010exposure prophylaxis (PrEP\/PEP) for human immunodeficiency virus (HIV) because of concerns about altered viral kinetics. We assessed the impact of the switch from a time\u2010based deferral for men who have sex with men (MSM) to sexual risk behaviour criteria on PrEP\/PEP deferrals.<\/jats:p><\/jats:sec>Materials and Methods<\/jats:title>Data on PrEP\/PEP deferral codes were extracted from our National Epidemiology Database for the 22 months before (Period 1) and after (Period 2) the criteria change.<\/jats:p><\/jats:sec>Results<\/jats:title>PEP deferrals remained stable (2.3 vs. 1.7 per 100,000 donations in Periods 1 and 2, p<\/jats:italic>\u2009=\u20090.2892), about 45% and 33%, respectively, of these donors who reported a recent needle stick injury. PrEP deferrals increased from 5.9 to 12.4 per 100,000 (p<\/jats:italic>\u2009=\u20090.0001); approximately 30% of donors in both periods had other HIV risk factor deferrals. Donors deferred for PrEP use alone were more likely to be male, first\u2010time users and younger than other donors.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The switch to sexual risk behaviour led to a small increase in deferrals for PrEP. We may not be measuring the full impact of deferral criteria because potential donors may self\u2010defer and PrEP use is increasing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13773","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:14:02Z","timestamp":1732234442000},"page":"193-196","source":"Crossref","is-referenced-by-count":1,"title":["Has the switch to sexual risk behaviour screening impacted deferrals for pre\u2010 and post\u2010exposure prophylaxis therapy for human immunodeficiency virus?"],"prefix":"10.1111","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-9952","authenticated-orcid":false,"given":"Mindy","family":"Goldman","sequence":"first","affiliation":[{"name":"Canadian Blood Services Medical Affairs and Innovation Ottawa Ontario Canada"},{"name":"Department of Pathology and Laboratory Medicine University of Ottawa Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samra","family":"Uzicanin","sequence":"additional","affiliation":[{"name":"Canadian Blood Services Medical Affairs and Innovation Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2789","authenticated-orcid":false,"given":"Sheila F.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Canadian Blood Services Medical Affairs and Innovation Ottawa Ontario Canada"},{"name":"School of Epidemiology and Public Health University of Ottawa Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.220645"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13011"},{"key":"e_1_2_9_4_1","unstructured":"Food and Drug Administration.Recommendations for Evaluating Donor Eligibility Using Individual Risk\u2010Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products.2023. Available from:https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/recommendations\u2010evaluating\u2010donor\u2010eligibility\u2010using\u2010individual\u2010risk\u2010based\u2010questions\u2010reduce\u2010risk\u2010human. Last accessed 15 Jul 2024."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13587"},{"key":"e_1_2_9_6_1","unstructured":"Public Health Agency of Canada.HIV in Canada: 2022 surveillance highlights. Available from:https:\/\/www.canada.ca\/en\/public\u2010health\/services\/publications\/diseases\u2010conditions\/hiv\u20102022\u2010surveillance\u2010highlights.html. Last accessed 22 Aug 2024."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16349"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v49i06a04"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.11.2300135"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107222"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:10:17Z","timestamp":1740111017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/vox.13773"],"URL":"https:\/\/doi.org\/10.1111\/vox.13773","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}